MCK

McKesson’s moat is scale and execution in U.S. pharmaceutical distribution, where massive volume, compliance infrastructure, and embedded customer relationships make the model hard to replicate even if unit margins are thin. The company is also building higher-quality profit streams in specialty/oncology services and prescription technology solutions, which can compound earnings faster than revenue. Industry consolidation and manufacturer/provider complexity generally favor the largest “toll-road” distributors, but customer concentration and contract repricing remain structural pressures.

Financially, momentum is solid: fiscal 2026 Q3 (ended December 31, 2025) revenue was $106.2B (+11% YoY) and EPS was $9.59, and management raised and narrowed full-year FY26 adjusted EPS guidance to $38.80–$39.20. Earlier in FY26, first-half free cash flow was $1.1B (operating cash flow $1.5B less capex $385M), and FY26 free cash flow outlook has been communicated around $4.4B–$4.8B, supporting buybacks and a modest dividend (about $3.28 annualized, low yield). Valuation looks reasonable rather than cheap: MCK trades around ~25x trailing earnings and ~19–20x forward, while price-to-sales is extremely low (~0.27) given the high-revenue/low-margin mix and ~ $106B market cap.

Over the next 12 months, the key bull case is continued mix-shift to specialty and RxTS plus execution that keeps FY26 results near the top of the $38.80–$39.20 range into FY27 setup. Catalysts include the May 2026 earnings update and any incremental share repurchase acceleration if cash conversion holds. Key risks are opioid-related legal exposure, contract renewals/pricing, and operational disruption (including cyber) in a mission-critical supply chain.

Recommendation: HOLD. Strong earnings momentum and resilient cash generation are real, but the stock’s multiple is no longer obviously discounted for a low-margin distributor, so upside likely depends on further guidance raises and sustained specialty/RxTS outperformance.